MedTrace Logo

A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects

NCT04973735 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2021-07-22

No results posted yet for this study

Summary

A single center, randomized, doubled-blind, placebo-control and single ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of LY-CovMab Injection in Chinese healthy subjects.

Conditions

  • Covid19

Interventions

DRUG

LY-CovMab

single IV infusion

Sponsors & Collaborators

  • Shandong Boan Biotechnology Co., Ltd

    collaborator INDUSTRY

  • Luye Pharma Group Ltd.

    lead INDUSTRY

Principal Investigators

  • Hui Zhao, Dr · The Second Hospital of Anhui Medical University

  • Wei Hu, Dr · The Second Hospital of Anhui Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-10
Primary Completion
2021-05-01
Completion
2021-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04973735 on ClinicalTrials.gov